The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Enrique OcioDuring ASCO 2019, Chicago, US, Enrique M. Ocio, Marqués de Valdecilla University Hospital, Santander, ES, spoke to the MM Hub about the choice of induction regimens in newly diagnosed multiple myeloma (NDMM). The main focus of this interview is Enrique M. Ocio's clinical experience within Spain, and Europe.
The treatment of NDMM is split into transplant eligible (TE) and non-transplant eligible (NTE). In the TE patients, Enrique M. Ocio comments that bortezomib + thalidomide + dexamethasone (VTd) is the standard triplet used currently, though his preference would be to switch thalidomide to lenalidomide to reduce the rates of peripheral neuropathy associated with thalidomide. However, this is not currently approved by the European Medicines Agency (EMA), but it is hoped this will follow shortly. It was also noted that the incorporation of second generation proteasome inhibitors and monoclonal antibodies will further expand the options. In the NTE group, melphalan + prednisone + dexamethasone (MPD) is the standard, now with the option of addding daratumumab. Enrique M. Ocio concludes that we will shortly have numerous options to choose from in the NDMM setting, which will make clinical decisions difficult, but will be good news for the patients who will have more available therapies.
Enrique Ocio kindly gave his interview in Spanish, with the title: Regimenes de inducción en pacientes con MM de nuevo diagnóstico.
Induction regimens in NDMM: my clinical experience